Video-on-Demand Library

02 July 2024

Rachid Abbas, Angeliki Thanaspoulou, Marcel Wolbers

GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer’s disease. The GRADUATE studies were among the first pivotal trials in Alzheimer’s Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand. In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.

Part of Collection(s)

Topic(s)

Upcoming Events